+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drug of Abuse Testing Market - Global Forecast to 2030- Product Image
Drug of Abuse Testing Market - Global Forecast to 2030- Product Image
Sale

Drug of Abuse Testing Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896653
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drug of Abuse Testing Market grew from USD 1.87 billion in 2024 to USD 2.01 billion in 2025. It is expected to continue growing at a CAGR of 7.31%, reaching USD 2.86 billion by 2030.

Executive Summary Introduction to Drug of Abuse Testing Landscape

The drug of abuse testing landscape is undergoing a profound transformation driven by technological innovation, regulatory evolution, and heightened demand for rapid, reliable results. This executive summary presents an integrated analysis of current market drivers, industry shifts, and strategic imperatives for stakeholders across criminal justice, healthcare, workplace screening, and other end-user segments. Beginning with an overview of emerging assay platforms such as high-performance chromatographic and spectrometric methods alongside portable point-of-care systems, it traces how evolving regulatory frameworks and quality standards are reshaping testing protocols. The introduction also outlines the critical role of varied specimen matrices-blood, hair, saliva, sweat, and urine-each supported by techniques from gas chromatography-mass spectrometry and immunoassays to enzyme and radioimmunoassay formats. Taking into account diverse drug classes including cannabinoids, depressants, hallucinogens, opioids, and stimulants, this section establishes the foundation for deeper insights into market segmentation, regional dynamics, competitive positioning, and actionable recommendations. By offering a clear lens on current challenges and opportunities, it sets the stage for informed strategic planning and investment decisions in a market defined by both complexity and rapid progress.

Transformative Shifts Redefining the Drug of Abuse Testing Landscape

Testing paradigms have shifted dramatically as automation and miniaturization reduce turnaround times and expand access beyond centralized laboratories. Advances in spectrometric methods now detect trace fentanyl analogs and synthetic cannabinoids with unprecedented sensitivity, while point-of-care devices employing breath thermography and lateral-flow immunoassays facilitate on-site screening at treatment centers, clinics, and roadside checkpoints. Furthermore, regulatory bodies at federal and state levels have introduced tighter validation requirements and chain-of-custody controls, prompting laboratories and manufacturers to enhance quality management systems and invest in audit-ready documentation. The aftermath of the global health crisis accelerated adoption of remote collection kits and telehealth-enabled sample supervision, reinforcing the importance of home testing kits and secure digital reporting platforms. In parallel, the integration of artificial intelligence and machine learning into data analysis workflows is enabling predictive risk profiling and pattern recognition across diverse populations, from pre-employment workplace screening to sporting and military doping programs. Consequently, these transformative shifts are redefining competitive benchmarks, opening new avenues for collaboration between technology vendors, service providers, and regulatory authorities.

Cumulative Impact of United States Tariffs 2025 on Testing Market

The imposition of additional duties on imported reagents, instrumentation, and consumables under the 2025 United States tariff schedule has compounded cost pressures across the supply chain. Laboratory operators reliant on high-precision chromatographic columns and mass spectrometry consumables now face increased acquisition expenses, compelling many to explore domestic sourcing options or enter into long-term procurement agreements to stabilize pricing. In healthcare settings, hospitals and clinics have reported extended lead times for critical assay kits, while criminal justice institutions and traffic enforcement agencies are adjusting budgets to account for higher per-test expenditures. Although some cost increases have been partially absorbed by volume discounts or offset through process efficiencies, a significant share has been passed downstream, driving end-user facilities to seek bundled service contracts or adopt direct purchase models to secure favorable terms. These dynamics are likely to intensify consolidation trends among testing service providers and accelerate investment in automated workflows that reduce per-sample handling costs, ensuring continuity of operations despite tariff-related headwinds.

Key Segmentation Insights Driving Market Dynamics

A multi-layered segmentation framework reveals the nuances underpinning market demand and technological adoption. Test type preferences span blood testing for therapeutic compliance monitoring; hair testing for extended detection windows; saliva and sweat testing for noninvasive, on-site screening; and urine testing anchored by gas chromatography-mass spectrometry alongside immunoassay platforms subdivided into enzyme immunoassay and radioimmunoassay techniques. End-users range from criminal justice agencies implementing evidentiary chains of custody to drug treatment centers aiming to measure rehabilitation outcomes, hospitals and clinics integrating testing into patient workflows, traffic law enforcement deploying rapid roadside kits, and diverse workplace screening environments balancing pre-employment due diligence with random testing protocols. Drug type coverage extends across cannabinoids-encompassing both synthetic analogs and THC-depressants such as barbiturates and benzodiazepines, hallucinogens including LSD and MDMA, opioids with a focus on fentanyl, heroin, and oxycodone, and stimulants like amphetamines, cocaine, and methamphetamines. Purpose-driven demand spans military and sports doping controls, legal investigations requiring forensic-grade results, and medical diagnosis applications guiding treatment decisions. Facility types include laboratory-centric testing through private and public health labs, as well as point-of-care solutions delivered via home testing kits or onsite platforms. Underlying all of these segments is a technological trifecta of breath thermography, chromatographic methods, and spectrometric approaches, procured through either contracts and agreements or direct purchase models. This granular view highlights pockets of high growth potential-particularly in rapid, noninvasive testing formats and forensic-grade applications-guiding resource allocation for both established players and new entrants.

Key Regional Insights Shaping Growth and Demand

Regional demand patterns underscore the critical role of established infrastructure in the Americas, where comprehensive regulatory frameworks and mature laboratory networks support broad adoption of both centralized and decentralized testing. In Europe, Middle East & Africa, complex cross-border regulations and diverse reimbursement systems create both challenges and opportunities for service providers capable of navigating varied market access pathways. This region boasts strong demand in forensic applications, where collaboration among law enforcement agencies and public health laboratories drives growth. Meanwhile, Asia-Pacific shows the fastest expansion of testing programs, fueled by government initiatives in China and India to strengthen workplace safety and public health surveillance. Investments in localized manufacturing and scale-up of point-of-care diagnostics are creating more affordable solutions that address rural and urban populations alike. Across all regions, interoperability of data systems and harmonization of quality standards emerge as pivotal factors influencing adoption rates and strategic partnerships.

Key Company Insights and Competitive Positioning

The competitive landscape is anchored by global leaders deploying integrated testing platforms and comprehensive assay portfolios. Abbott Laboratories and Thermo Fisher Scientific drive innovation through high-throughput chromatographic and spectrometric solutions, while Danaher Corporation and GE Healthcare Inc. focus on expanding point-of-care offerings. Merck KGaA and F. Hoffmann-La Roche Ltd leverage deep R&D pipelines to introduce next-generation immunoassays. Laboratory Corporation of America Holdings, Quest Diagnostics, and Clinical Reference Laboratory, Inc. dominate service delivery with extensive networks of private and public health labs, complemented by Precision Diagnostic Services Inc and Legacy Healthcare Services, Inc. specializing in customized testing programs. Drägerwerk AG & Co. KGaA and Express Diagnostics International target niche segments such as traffic enforcement and correctional facilities. Pharmaceutical heavyweights Pfizer Inc and Sanofi SA maintain strategic positions through partnerships and licensing agreements. Mayo Collaborative Services, Inc. and Psychemedics Corporation exemplify specialized centers of excellence in forensic and hair testing, respectively. Siemens Healthineers AG continues to integrate AI-driven analytics into diagnostic workflows, setting new benchmarks for automation and data management. Together, these companies shape a dynamic ecosystem where innovation, scale, and regulatory acumen determine market leadership.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize diversification of supply chains by forging strategic alliances with domestic and regional suppliers of critical reagents and consumables. Investing in flexible manufacturing platforms and modular point-of-care devices will mitigate tariff-induced disruptions and deliver cost-effective testing solutions. Embrace artificial intelligence and data analytics to streamline result interpretation and predictive risk assessment, bolstering service quality across end-user verticals. Expand assay portfolios to address emerging threats such as novel synthetic opioids and designer cannabinoids, while differentiating through rapid-response formats tailored for roadside, workplace, and home use cases. Pursue joint ventures and co-development agreements with digital health providers to integrate remote specimen collection kits and telehealth supervision into care pathways. In parallel, engage proactively with regulatory agencies to influence guideline updates and ensure seamless market access. Finally, explore growth opportunities in under-penetrated Asia-Pacific and EMEA markets by customizing offerings to local regulatory requirements and reimbursement models.

Conclusion and Strategic Imperatives

In today’s complex environment, success hinges on balancing technological innovation with operational agility. Laboratories and manufacturers must internalize the lessons of recent regulatory reforms and tariff pressures, embedding resilience into procurement, production, and service delivery processes. By aligning R&D investments with evolving detection needs-from emerging drug classes to noninvasive matrices-organizations can stay ahead of competitive and compliance challenges. Simultaneously, strengthening partnerships across the value chain, from raw material suppliers to clinical and forensic end-users, will unlock synergies that drive efficiency and market reach. Ultimately, a forward-looking strategy that embraces digital transformation, localized manufacturing, and targeted regional expansion will position stakeholders for sustainable growth in a market defined by rising demand for precision, speed, and reliability.

Market Segmentation & Coverage

This research report categorizes the Drug of Abuse Testing Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Blood Testing
  • Hair Testing
  • Saliva Testing
  • Sweat Testing
  • Urine Testing
    • Gas Chromatography-Mass Spectrometry
    • Immunoassay Testing
      • Enzyme Immunoassay
      • Radioimmunoassay
  • Criminal Justice
  • Drug Treatment Centers
  • Hospitals and Clinics
  • Traffic Law Enforcement
  • Workplace Screening
    • Pre-Employment Screening
    • Random Testing
  • Cannabinoids
    • Synthetic Cannabinoids
    • THC
  • Depressants
    • Barbiturates
    • Benzodiazepines
  • Hallucinogens
    • LSD
    • MDMA
  • Opioids
    • Fentanyl
    • Heroin
    • Oxycodone
  • Stimulants
    • Amphetamines
    • Cocaine
    • Methamphetamines
  • Doping Testing
    • Military Doping
    • Sports Doping
  • Legal Investigation
  • Medical Diagnosis
  • Laboratory Testing
    • Private Labs
    • Public Health Labs
  • Point of Care Testing
    • Home Testing Kits
    • Onsite Testing
  • Breath Thermography
  • Chromatographic Methods
  • Spectrometric Methods
  • Contracts and Agreements
  • Direct Purchase

This research report categorizes the Drug of Abuse Testing Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Drug of Abuse Testing Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Clinical Reference Laboratory, Inc.
  • Danaher Corporation
  • Drgerwerk AG & Co. KGaA
  • Express Diagnostics International
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare Inc.
  • Laboratory Corporation of America Holdings
  • Legacy Healthcare Services, Inc.
  • Mayo Collaborative Services, Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Precision Diagnostic Services Inc
  • Psychemedics Corporation
  • Quest Diagnostics
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drug of Abuse Testing Market, by Test Type
8.1. Introduction
8.2. Blood Testing
8.3. Hair Testing
8.4. Saliva Testing
8.5. Sweat Testing
8.6. Urine Testing
8.6.1. Gas Chromatography-Mass Spectrometry
8.6.2. Immunoassay Testing
8.6.2.1. Enzyme Immunoassay
8.6.2.2. Radioimmunoassay
9. Drug of Abuse Testing Market, by End-User
9.1. Introduction
9.2. Criminal Justice
9.3. Drug Treatment Centers
9.4. Hospitals and Clinics
9.5. Traffic Law Enforcement
9.6. Workplace Screening
9.6.1. Pre-Employment Screening
9.6.2. Random Testing
10. Drug of Abuse Testing Market, by Drug Type
10.1. Introduction
10.2. Cannabinoids
10.2.1. Synthetic Cannabinoids
10.2.2. THC
10.3. Depressants
10.3.1. Barbiturates
10.3.2. Benzodiazepines
10.4. Hallucinogens
10.4.1. LSD
10.4.2. MDMA
10.5. Opioids
10.5.1. Fentanyl
10.5.2. Heroin
10.5.3. Oxycodone
10.6. Stimulants
10.6.1. Amphetamines
10.6.2. Cocaine
10.6.3. Methamphetamines
11. Drug of Abuse Testing Market, by Purpose
11.1. Introduction
11.2. Doping Testing
11.2.1. Military Doping
11.2.2. Sports Doping
11.3. Legal Investigation
11.4. Medical Diagnosis
12. Drug of Abuse Testing Market, by Facility Type
12.1. Introduction
12.2. Laboratory Testing
12.2.1. Private Labs
12.2.2. Public Health Labs
12.3. Point of Care Testing
12.3.1. Home Testing Kits
12.3.2. Onsite Testing
13. Drug of Abuse Testing Market, by Technology
13.1. Introduction
13.2. Breath Thermography
13.3. Chromatographic Methods
13.4. Spectrometric Methods
14. Drug of Abuse Testing Market, by Mode of Procurement
14.1. Introduction
14.2. Contracts and Agreements
14.3. Direct Purchase
15. Americas Drug of Abuse Testing Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Drug of Abuse Testing Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Drug of Abuse Testing Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. Bio-Rad Laboratories, Inc.
18.3.3. Clinical Reference Laboratory, Inc.
18.3.4. Danaher Corporation
18.3.5. Drgerwerk AG & Co. KGaA
18.3.6. Express Diagnostics International
18.3.7. F. Hoffmann-La Roche Ltd
18.3.8. GE Healthcare Inc.
18.3.9. Laboratory Corporation of America Holdings
18.3.10. Legacy Healthcare Services, Inc.
18.3.11. Mayo Collaborative Services, Inc.
18.3.12. Merck KGaA
18.3.13. Pfizer Inc.
18.3.14. Precision Diagnostic Services Inc
18.3.15. Psychemedics Corporation
18.3.16. Quest Diagnostics
18.3.17. Sanofi SA
18.3.18. Siemens Healthineers AG
18.3.19. Thermo Fisher Scientific Inc
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. DRUG OF ABUSE TESTING MARKET MULTI-CURRENCY
FIGURE 2. DRUG OF ABUSE TESTING MARKET MULTI-LANGUAGE
FIGURE 3. DRUG OF ABUSE TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. DRUG OF ABUSE TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. DRUG OF ABUSE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUG OF ABUSE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY BLOOD TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SALIVA TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SWEAT TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CRIMINAL JUSTICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TRAFFIC LAW ENFORCEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY PRE-EMPLOYMENT SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY RANDOM TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SYNTHETIC CANNABINOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY THC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY BARBITURATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LSD, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY MDMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FENTANYL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HEROIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY OXYCODONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COCAINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY METHAMPHETAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY MILITARY DOPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SPORTS DOPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LEGAL INVESTIGATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY MEDICAL DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOME TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ONSITE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY BREATH THERMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SPECTROMETRIC METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CONTRACTS AND AGREEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 128. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 129. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 130. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 131. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 133. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 134. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 135. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 136. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 137. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 138. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 139. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 140. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 141. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 142. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 143. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 144. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 145. CANADA DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 146. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 147. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 148. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 149. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 151. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 153. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 154. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 156. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 157. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 158. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 159. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 160. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 161. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 162. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 163. MEXICO DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 220. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 221. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 222. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 223. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 225. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 226. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 227. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 228. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 229. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 230. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 231. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 232. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 233. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 234. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 235. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 236. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 238. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 239. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 240. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 241. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 242. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 243. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 244. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 245. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 246. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 247. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 248. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 249. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 250. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 251. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 252. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 253. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 254. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 255. INDIA DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 261. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 264. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 266. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 267. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 268. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 269. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 274. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 275. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 276. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 277. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 278. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 279. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 280. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 281. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 282. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 283. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 284. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 285. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 286. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 287. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 288. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 289. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 290. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 291. JAPAN DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 309. MALAYSIA DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 310. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 311. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 312. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 313. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 314. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 315. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 316. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 317. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 318. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY HALLUCINOGENS, 2018-2030 (USD MILLION)
TABLE 319. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
TABLE 320. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY STIMULANTS, 2018-2030 (USD MILLION)
TABLE 321. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY PURPOSE, 2018-2030 (USD MILLION)
TABLE 322. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY DOPING TESTING, 2018-2030 (USD MILLION)
TABLE 323. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
TABLE 324. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 325. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 326. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES DRUG OF ABUSE TESTING MARKET SIZE, BY MODE OF PROCUREMENT, 2018-2030 (USD MILLION)
TABLE 328. SINGAPORE DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 329. SINGAPORE DRUG OF ABUSE TESTING MARKET SIZE, BY URINE TESTING, 2018-2030 (USD MILLION)
TABLE 330. SINGAPORE DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY TESTING, 2018-2030 (USD MILLION)
TABLE 331. SINGAPORE DRUG OF ABUSE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 332. SINGAPORE DRUG OF ABUSE TESTING MARKET SIZE, BY WORKPLACE SCREENING, 2018-2030 (USD MILLION)
TABLE 333. SINGAPORE DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 334. SINGAPORE DRUG OF ABUSE TESTING MARKET SIZE, BY CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 335. SINGAPORE DRUG OF ABUSE TESTING MARKET SIZE, BY DEPRESSANTS, 2018-2030 (USD MILLION)
TABLE 336. SIN

Companies Mentioned

  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Clinical Reference Laboratory, Inc.
  • Danaher Corporation
  • Drgerwerk AG & Co. KGaA
  • Express Diagnostics International
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare Inc.
  • Laboratory Corporation of America Holdings
  • Legacy Healthcare Services, Inc.
  • Mayo Collaborative Services, Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Precision Diagnostic Services Inc
  • Psychemedics Corporation
  • Quest Diagnostics
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc

Methodology

Loading
LOADING...

Related Topics

Related Reports

At-home Drug of Abuse Testing Market by Product, Test Type, Drug, Distribution Channel - Global Forecast 2025-2030 - Product Image

At-home Drug of Abuse Testing Market by Product, Test Type, Drug, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Drug Of Abuse Testing Services Market Size, Share & Trends Analysis Report By Drug (Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD), By Region And Segment Forecasts, 2025 - 2030 - Product Image

Drug Of Abuse Testing Services Market Size, Share & Trends Analysis Report By Drug (Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD), By Region And Segment Forecasts, 2025 - 2030

  • Report
  • 125 Pages
  • Global
From
Drug of Abuse Testing Market (By Product Type, Sample / Test Type, Drug Type, End Users / Setting Type, Country Analysis), Regulatory Status, Recent Developments, Company Profiles - Forecast to 2032 - Product Image

Drug of Abuse Testing Market (By Product Type, Sample / Test Type, Drug Type, End Users / Setting Type, Country Analysis), Regulatory Status, Recent Developments, Company Profiles - Forecast to 2032

  • Report
  • 235 Pages
  • Global
From
Drug Abuse Testing Market Report by Product, Sample (Urine, Oral Fluid, Hair, Breath, and Others), End User, and Region 2024-2032 - Product Image

Drug Abuse Testing Market Report by Product, Sample (Urine, Oral Fluid, Hair, Breath, and Others), End User, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
At-Home Drug of Abuse Testing Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

At-Home Drug of Abuse Testing Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.